

## Mipomersen

Cat. No.:	HY-148647
CAS No.:	1000120-98-8
Molecular Weight:	7177
Target:	HCV
Pathway:	Anti-infection
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

# Mipomersen

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : ≥ 100 mg/mL (13.93 mM)  
\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		Concentration	1 mg	5 mg	10 mg
	1 mM		0.1393 mL	0.6967 mL	1.3933 mL
	5 mM		0.0279 mL	0.1393 mL	0.2787 mL
	10 mM		0.0139 mL	0.0697 mL	0.1393 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH)<sup>[1][2]</sup>.

#### In Vitro

Mipomersen (800 and 1000 µg/mL; 72 hours) reduces 80%-85% intracellular HCV RNA in Huh7/CD81 WT cells with HCVcc (JFH1) infection<sup>[2]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Mipomersen (25 mg/kg; i.p., twice weekly for 11 weeks) affects levels of h-apoB, h-apoB-100, Lp(a) and OxPL/h-apoB<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Transgenic mice overexpressing human apolipoprotein B-100 (h-apoB mice) or h-apoB-100 plus human apo(a) (Lp(a) mice) <sup>[1]</sup>
Dosage:	25 mg/kg

---

Administration:	Intraperitoneal injection; 25 mg/kg, twice weekly for 11 weeks
Result:	Time-dependently reduced the level of h-apoB-100 in Lp(a) mice and h-apoB in h-apoB mice.

---

## REFERENCES

---

- [1]. Merki E, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. *Circulation*. 2008 Aug 12;118(7):743-53.
- [2]. Schaefer EA, et al. Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. *World J Gastroenterol*. 2016 Dec 7;22(45):9954-9965.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA